Skip to main navigation Skip to search Skip to main content

Cogent Biosciences Announces Positive Top-Line Results Achieving Statistical Significance Across All Primary And Key Secondary Endpoints From The SUMMIT Trial Of Bezuclastinib In Patients With Non-Advanced Systemic Mastocytosis

Press/Media

Period7 Jul 20258 Jul 2025

Media coverage

26

Media coverage